Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Department of Pathology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Cell Oncol (Dordr). 2020 Jun;43(3):489-503. doi: 10.1007/s13402-020-00506-8. Epub 2020 Apr 16.
Persistent infection with high-risk human papillomavirus (HR-HPV) is thought to play a prominent role in the initiation and progression of almost all cases of cervical cancer. Previously, we and others found that microRNA 34a (miR-34a) may be regulated by HR-HPV E6 to contribute to the development of cervical cancer. Here, we aimed to identify the oncogenic potential and clinical significance of a known miR-34a target, WNT1, in cervical squamous cell carcinoma (SCC) development and to investigate the associated mechanisms underlying cervical SCC cell proliferation and invasion.
WNT1 and miR-34a expression levels were assessed in primary cervical lesions using immunohistochemistry and qRT-PCR, respectively. The cellular effects and the expression of its associated genes were examined in cervical SCC-derived Siha and Caski cells after siRNA-WNT1 (downregulation) or miR-34a mimic (upregulation) treatment. A cervical SCC xenograft mouse model was used to investigate the in vivo effects of miR-34a overexpression. HPV-16 E6/E7 expression was inhibited by gene promoter siRNA targeting, after which the levels of miR-34a and WNT1 were examined.
WNT1 protein upregulation was found to be associated with a poor prognosis in cervical SCC patients. In vitro assays in Siha and Caski cells revealed that WNT1 downregulation decreased cell proliferation and invasion, inhibited WNT/β-catenin activation and affected the expression of E-cadherin and P-cadherin. MiR-34a upregulation resulted in decreased WNT1 expression. An inverse correlation between miR-34a and WNT1 expression was also observed in primary cervical SCC tissues. In addition, we found that MiR-34a could regulate an E-cadherin to P-cadherin switch (E-P cadherin switch) to inhibit cell proliferation and tumorigenesis in vitro and in vivo via inactivation of the WNT1/β-catenin pathway. Finally, we found that decreased HPV-16 E6/E7 expression resulted in miR-34a upregulation and WNT1 downregulation in Siha and Caski cells.
From our results we conclude that WNT1, as a target of miR-34a, can promote cervical SCC cell proliferation and invasion by induction of an E-P cadherin switch via the WNT1/β-catenin pathway. Our results may provide new options for the treatment of patients with cervical SCC.
高危型人乳头瘤病毒(HR-HPV)的持续感染被认为在几乎所有宫颈癌病例的发生和进展中起重要作用。此前,我们和其他人发现微小 RNA 34a(miR-34a)可能受到 HR-HPV E6 的调控,从而有助于宫颈癌的发展。在这里,我们旨在确定已知的 miR-34a 靶标 WNT1 在宫颈鳞状细胞癌(SCC)发展中的致癌潜能和临床意义,并研究与宫颈 SCC 细胞增殖和侵袭相关的潜在机制。
使用免疫组织化学和 qRT-PCR 分别评估原发性宫颈病变中的 WNT1 和 miR-34a 表达水平。在用 siRNA-WNT1(下调)或 miR-34a 模拟物(上调)处理宫颈 SCC 衍生的 Siha 和 Caski 细胞后,检测细胞效应及其相关基因的表达。使用宫颈 SCC 异种移植小鼠模型研究 miR-34a 过表达的体内效应。通过针对基因启动子的 siRNA 抑制 HPV-16 E6/E7 的表达,然后检测 miR-34a 和 WNT1 的水平。
发现 WNT1 蛋白上调与宫颈癌患者预后不良有关。在 Siha 和 Caski 细胞中的体外试验表明,下调 WNT1 可降低细胞增殖和侵袭,抑制 WNT/β-catenin 激活,并影响 E-钙粘蛋白和 P-钙粘蛋白的表达。miR-34a 的上调导致 WNT1 表达减少。在原发性宫颈 SCC 组织中也观察到 miR-34a 和 WNT1 表达之间的负相关关系。此外,我们发现 miR-34a 可以通过失活 WNT1/β-catenin 通路来调节 E-钙粘蛋白到 P-钙粘蛋白的转换(E-P 钙粘蛋白转换),从而抑制体外和体内的细胞增殖和肿瘤发生。最后,我们发现 HPV-16 E6/E7 表达降低导致 Siha 和 Caski 细胞中 miR-34a 的上调和 WNT1 的下调。
从我们的结果中我们得出结论,WNT1 作为 miR-34a 的靶标,可以通过诱导 E-P 钙粘蛋白转换通过 WNT1/β-catenin 通路促进宫颈 SCC 细胞的增殖和侵袭。我们的结果可能为治疗宫颈癌患者提供新的选择。